Who are we?
Unipharm was founded in 1975 in Israel and since its early days has been a dominant player in the pharmaceutical arena in Israel.
What do we do?
We create value in the full pharmaceutical value chain from, developing to manufacturing and successfully marketing generic pharmaceuticals. We take pride in doing this in an innovative, responsible, and cost-efficient way.
What do we offer?
We offer a product portfolio consisting of a broad range of high quality generics for all major therapeutic areas. It is part of our long-term strategy to expand the product portfolio of off-patent blockbusters, while at the same time offering a broader range of niche products within more narrow disease areas.
Unipharm’s products are in CTD dossier format and are produced in Unipharm’s state-of-the-art manufacturing facility in Israel, a certified Good Manufacturing Practices (GMP) facility, which is recognized by the European Union (EU).
Our unique added value
Unipharm is known in Israel for its successful track record of patent litigations against the originators.
In the current pharmaceutical-IP environment where major pharmaceutical companies are protecting their product with multiple patents, Unipharm has the capabilities to accurately evaluate a product’s patent protection suit and to act accordingly: either stay off the market until the patents expire, circumvent the still valid patents, or try to invalidate the patent and launch a generic version as soon as legally possible.